NCT03941262View on ClinicalTrials.gov

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

February 17, 2023

Study Completion Date

February 17, 2023

Conditions
Refractory CancerMetastatic CancerRecurrent CancerUnresectable CarcinomaSolid Tumor, AdultAdvanced CancerAdvanced Solid Tumor
Interventions
BIOLOGICAL

SNK01

Patient-specific ex vivo expanded autologous natural killer cells

DRUG

Avelumab

Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).

DRUG

Pembrolizumab

Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).

Trial Locations (1)

90403

Sarcoma Oncology Research Center, Santa Monica

Sponsors
All Listed Sponsors
lead

NKGen Biotech, Inc.

INDUSTRY

NCT03941262 - Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | Biotech Hunter | Biotech Hunter